Actuate Therapeutics Inc.

Quick facts

Phase 2 pipeline

• Gemcitabine - 21 day cycle · Oncology
  Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha
• Gemcitabine - 28 day cycle · Oncology
  Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Actuate Therapeutics Inc. portfolio CI brief
• Actuate Therapeutics Inc. pipeline updates RSS